Full Press Release Details
InspireMD Appoints Rick Olson as Vice
President of Global Sales Operations
Company Strengthens Leadership Team with
Addition of Experienced Global Sales Executive
BOSTON, MA - December 2, 2013
- InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"),
a leader in embolic protection systems, today announced the appointment of Rick Olson as Vice President of Global Sales Operations
based in the United Kingdom.
Mr. Olson, 52, will be responsible for
fully implementing the global sales strategy the Company has developed over the past several months. Also, his extensive experience
in coronary, vascular and peripheral product sales will enable the Company to begin to advance commercial efforts across all three
Mr. Olson is a 25-year global sales, marketing
and management executive with expertise in developing and executing strategies to achieve scalable growth for an array of novel
medical device technology companies, including Boston Scientific and Covidien. Prior to joining InspireMD, Mr. Olson served as
the Director of International Strategy and HPMS (High Performance Management System) at Covidien. Before it was acquired by Covidien,
Mr. Olson was Director of International Neurovascular Marketing & Sales Force Development at ev3, Inc., where he initiated
market development and sales execution strategies for all OUS markets. During his tenure with ev3, revenues increased from less
than $5 million to over $400 million in sales leading up to the acquisition of ev3 by Covidien in 2008. Prior to that, Mr. Olson
spent nine years at Boston Scientific where he served in various sales and marketing leadership positions both in Europe and the
United States. Mr. Olson holds a Bachelor's Degree in Psychology from Oregon State University.
"We are delighted to have Rick join
the team at this important time in the Company's commercialization efforts" commented Alan Milinazzo, Chief Executive
Officer of InspireMD. "Rick has a strong track record of building successful sales organizations in the coronary, vascular
and peripheral therapeutic markets. His ability to positively lead our organization in all three therapeutic areas is a tremendous
benefit to our commercial efforts as we enter the next phase of our selling activities. Further, Rick's success in implementing
highly efficient and successful sales strategies has spanned virtually all geographies. This allows us to advance our current market
strategies and evaluate new markets across all therapeutic areas."
In connection with his appointment, InspireMD
made an inducement grant to Mr. Olson pursuant to a stand-alone award agreement outside of InspireMD's 2011 Umbrella Option
Plan as an inducement material to Mr. Olson entering into employment with InspireMD in accordance with Section 711(a) of the NYSE
MKT Company Guide. The inducement grant was approved by the compensation committee of InspireMD's board of directors, which
is comprised solely of independent directors. Mr. Olson's inducement grant consists of a stock option to purchase up to 150,000
shares of InspireMD's common stock, with a per share exercise price equal to the closing price of the Company's common
stock on December 2, 2013, the first trading day following the effective date of Mr. Olson's employment with InspireMD. Mr.
Olson's option vests and becomes exercisable in three equal annual installments beginning on the one-year anniversary of
the date of grant, subject to his continuous service through each vesting date. The option has a term of 10 years from the date
About Stenting and MGuard EPS
Standard stents were not engineered for
heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion
in a heart attack patient.
In acute heart attack patients, the plaque
or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal)
in a significant portion of heart attack patients.
The MGuard EPS is integrated with a precisely
engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage
While offering superior performance relative
to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician
practice - an important factor in promoting acceptance and general use in time-critical emergency settings.
The MGuard EPS is CE Mark approved. It
is not approved for sale in the U.S. by the FDA at this time. This release is for the sole purpose of informing the investing community
and is no way intended to market or promote the MGuard EPS or any other InspireMD product to consumers or prospective patients
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary
MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution
to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse
InspireMD intends to pursue applications
of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under
the ticker symbol NSPR.
Forward-looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks
and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results
or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi)
our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the
fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising
may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing
us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with
foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk
factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors
and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company
assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com
Samantha Wolf / Taylor McGrann
KCSA Strategic Communications
212-896-1220 / 212-896-1253